Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients
Background
Patients with end-stage renal disease are at increased risk for sudden cardiac death, although the utility of implantable cardioverter-defibrillators (ICDs) in these patients is unknown.
Objectives
The purpose of this study was to evaluate whether end-stage renal disease is an independent risk factor for appropriate ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF) and to compare the long-term survival of ICD recipients with and without end-stage renal disease.
Methods
A retrospective cohort study was performed on ICD recipients at a single center. The primary endpoint was first appropriate ICD therapy for VT/VF. The secondary endpoint was survival.
Results
The study included 585 patients, 19 (3.2%) of whom had end-stage renal disease prior to device implantation. Average follow-up time was 2.2 ± 2.4 years, during which time 156 patients (26.7%) received appropriate ICD therapy. End-stage renal disease was strongly associated with appropriate ICD therapy (hazard ratio 2.30, 95% confidence interval 1.17–4.54) and remained a significant predictor following adjustment for implant indication, ejection fraction, diabetes, hypertension, and beta-blocker use. Survival was significantly shorter in the end-stage renal disease patients, with a median survival time of 3.2 ± 0.6 (SEM) years in the dialysis cohort and 7.4 ± 0.5 (SEM) years in those without end-stage renal disease (log rank P = .009). The majority of deaths in the end-stage renal disease cohort were due to non–device-related infection.
Conclusion
In this cohort, end-stage renal disease was the single greatest predictor of ICD therapies for VT/VF. The survival rate was significantly shorter than that of ICD recipients without end-stage renal disease, suggesting that comorbidities in end-stage renal disease patients meeting current implant indications may reduce the survival benefit of ICD placement in this population.
Keywords: Sudden cardiac death , Implantable cardioverter-defibrillator , Dialysis , End-stage renal disease
To access this article, please choose from the options below
Dr. Passman is funded by National Institutes of Health Grant K23 HL068814-01. This project is unsponsored. Drs. Kadish and Goldberger receive research funding from Medtronic, Guidant, and St. Jude. Dr. Passman receives research funding from Medtronic and St. Jude and receives salary support from a National Institutes of Health K23 award.
PII: S1547-5271(06)01709-7
doi:10.1016/j.hrthm.2006.06.013
© 2006 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
